Form 8-K - Current report:
SEC Accession No. 0001193125-24-111481
Filing Date
2024-04-25
Accepted
2024-04-25 06:46:02
Documents
15
Period of Report
2024-04-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d800679d8k.htm   iXBRL 8-K 25237
2 EX-99.1 d800679dex991.htm EX-99.1 76671
6 GRAPHIC g800679g0425040144495.jpg GRAPHIC 1859
  Complete submission text file 0001193125-24-111481.txt   239594

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20240425.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240425_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240425_pre.xml EX-101.PRE 10810
19 EXTRACTED XBRL INSTANCE DOCUMENT d800679d8k_htm.xml XML 3551
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 24872797
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)